

Charles L Sentman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9084902/publications.pdf>

Version: 2024-02-01

55
papers

3,347
citations

126907

33
h-index

175258

52
g-index

57
all docs

57
docs citations

57
times ranked

3873
citing authors

#	ARTICLE	IF	CITATIONS
1	Bispecific Tâ€cell engagers for cancer immunotherapy. <i>Immunology and Cell Biology</i> , 2015, 93, 290-296.	2.3	279
2	Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma. <i>Cancer Immunology Research</i> , 2019, 7, 100-112.	3.4	220
3	NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma. <i>Cancer Research</i> , 2018, 78, 1031-1043.	0.9	193
4	NKG2D ligands as therapeutic targets. <i>Cancer Immunity</i> , 2013, 13, 8.	3.2	168
5	Recruitment of Uterine NK Cells: Induction of CXC Chemokine Ligands 10 and 11 in Human Endometrium by Estradiol and Progesterone. <i>Journal of Immunology</i> , 2004, 173, 6760-6766.	0.8	147
6	Chimeric NK-receptorâ€bearing T cells mediate antitumor immunotherapy. <i>Blood</i> , 2005, 106, 1544-1551.	1.4	138
7	Unique phenotype of human uterine NK cells and their regulation by endogenous TGF-Î². <i>Journal of Leukocyte Biology</i> , 2004, 76, 667-675.	3.3	130
8	Generation of Antitumor Responses by Genetic Modification of Primary Human T Cells with a Chimeric NKG2D Receptor. <i>Cancer Research</i> , 2006, 66, 5927-5933.	0.9	120
9	An Nkp30-Based Chimeric Antigen Receptor Promotes T Cell Effector Functions and Antitumor Efficacy In Vivo. <i>Journal of Immunology</i> , 2012, 189, 2290-2299.	0.8	106
10	Depletion of Dendritic Cells Delays Ovarian Cancer Progression by Boosting Antitumor Immunity. <i>Cancer Research</i> , 2008, 68, 7684-7691.	0.9	105
11	Chimeric NKG2D Receptorâ€bearing T Cells as Immunotherapy for Ovarian Cancer. <i>Cancer Research</i> , 2007, 67, 5003-5008.	0.9	96
12	Chimeric Antigen Receptor T Cells Shape Myeloid Cell Function within the Tumor Microenvironment through IFN-Î³ and GM-CSF. <i>Journal of Immunology</i> , 2012, 188, 6389-6398.	0.8	92
13	Chimeric NKG2D Expressing T Cells Eliminate Immunosuppression and Activate Immunity within the Ovarian Tumor Microenvironment. <i>Journal of Immunology</i> , 2009, 183, 6939-6947.	0.8	85
14	NKG2D CARs as Cell Therapy for Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2014, 20, 156-159.	2.0	85
15	Inhibitory Receptors Alter Natural Killer Cell Interactions with Target Cells Yet Allow Simultaneous Killing of Susceptible Targets. <i>Journal of Experimental Medicine</i> , 1999, 190, 1005-1012.	8.5	82
16	Chimeric NKG2Dâ€Modified T Cells Inhibit Systemic T-Cell Lymphoma Growth in a Manner Involving Multiple Cytokines and Cytotoxic Pathways. <i>Cancer Research</i> , 2007, 67, 11029-11036.	0.9	81
17	Chimeric NKG2D receptorâ€expressing T cells as an immunotherapy for multiple myeloma. <i>Experimental Hematology</i> , 2008, 36, 1318-1328.	0.4	77
18	Immunotherapy with Chimeric NKG2D Receptors Leads to Long-Term Tumor-Free Survival and Development of Host Antitumor Immunity in Murine Ovarian Cancer. <i>Journal of Immunology</i> , 2008, 180, 72-78.	0.8	76

#	ARTICLE	IF	CITATIONS
19	TLRs Mediate IFN- γ Production by Human Uterine NK Cells in Endometrium. <i>Journal of Immunology</i> , 2006, 176, 6219-6224.	0.8	75
20	Antibody humanization by structure-based computational protein design. <i>MAbs</i> , 2015, 7, 1045-1057.	5.2	58
21	NKG2D CAR T cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors. <i>Immunology and Cell Biology</i> , 2013, 91, 435-440.	2.3	57
22	Cancer Immunotherapy Using a Bispecific NK Receptor Fusion Protein that Engages both T Cells and Tumor Cells. <i>Cancer Research</i> , 2011, 71, 2066-2076.	0.9	56
23	B7H6-Specific Bispecific T Cell Engagers Lead to Tumor Elimination and Host Antitumor Immunity. <i>Journal of Immunology</i> , 2015, 194, 5305-5311.	0.8	55
24	Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell-Treated Mice. <i>Journal of Immunology</i> , 2016, 197, 4674-4685.	0.8	50
25	NK cells rapidly remove B16F10 tumor cells in a perforin and interferon-gamma independent manner in vivo. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 1153-1161.	4.2	49
26	Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy. <i>Cytotherapy</i> , 2018, 20, 952-963.	0.7	49
27	NK Cell Receptors as Tools in Cancer Immunotherapy. <i>Advances in Cancer Research</i> , 2006, 95, 249-292.	5.0	46
28	Exploiting natural killer group 2D receptors for CAR T-cell therapy. <i>Future Oncology</i> , 2017, 13, 1593-1605.	2.4	46
29	Collaboration of chimeric antigen receptor (CAR)-expressing T cells and host T cells for optimal elimination of established ovarian tumors. <i>Oncolimmunology</i> , 2013, 2, e23564.	4.6	45
30	Human NK cell IFN- γ production is regulated by endogenous TGF- β . <i>International Immunopharmacology</i> , 2006, 6, 1020-1028.	3.8	40
31	Mouse Tumor Vasculature Expresses NKG2D Ligands and Can Be Targeted by Chimeric NKG2D-Modified T Cells. <i>Journal of Immunology</i> , 2013, 190, 2455-2463.	0.8	40
32	MHC Class I-Ly49 Interactions Shape the Ly49 Repertoire on Murine NK Cells. <i>Journal of Immunology</i> , 2001, 166, 6585-6592.	0.8	37
33	Bispecific T-Cell Engagers (BiTEs) as Treatment of B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 1131-1133.	1.6	37
34	Computationally-driven identification of antibody epitopes. <i>ELife</i> , 2017, 6, .	6.0	37
35	Chimeric NKG2D T Cells Require Both T Cell- and Host-Derived Cytokine Secretion and Perforin Expression to Increase Tumor Antigen Presentation and Systemic Immunity. <i>Journal of Immunology</i> , 2009, 183, 2365-2372.	0.8	34
36	DNAM-1-based chimeric antigen receptors enhance T cell effector function and exhibit in vivo efficacy against melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 409-418.	4.2	32

#	ARTICLE	IF	CITATIONS
37	Ly49A expression on T cells alters T cell selection. <i>International Immunology</i> , 2000, 12, 215-222.	4.0	30
38	How Chimeric Antigen Receptor Design Affects Adoptive T Cell Therapy. <i>Journal of Cellular Physiology</i> , 2016, 231, 2590-2598.	4.1	28
39	Advances in the use of natural receptor- or ligand-based chimeric antigen receptors (CARs) in haematologic malignancies. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 176-183.	1.7	25
40	Immunodeficient mice have elevated numbers of NK cells in non-lymphoid tissues. <i>Experimental Cell Research</i> , 2006, 312, 3920-3926.	2.6	20
41	NK Cell Function in the Human Female Reproductive Tract. <i>American Journal of Reproductive Immunology</i> , 2007, 57, 108-115.	1.2	20
42	NKG2D Ligand-Targeted Bispecific T-Cell Engagers Lead to Robust Antitumor Activity against Diverse Human Tumors. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1335-1346.	4.1	17
43	Development of unique cytotoxic chimeric antigen receptors based on human scFv targeting B7H6. <i>Protein Engineering, Design and Selection</i> , 2017, 30, 713-721.	2.1	14
44	Toxicity Induced by a Bispecific T Cell-Redirecting Protein Is Mediated by Both T Cells and Myeloid Cells in Immunocompetent Mice. <i>Journal of Immunology</i> , 2020, 204, 2973-2983.	0.8	14
45	Superkine IL-2 and IL-33 Armored CAR T Cells Reshape the Tumor Microenvironment and Reduce Growth of Multiple Solid Tumors. <i>Cancer Immunology Research</i> , 2022, 10, 962-977.	3.4	12
46	GFP transgenic mice show dynamics of lung macrophages. <i>Experimental Cell Research</i> , 2005, 310, 409-416.	2.6	11
47	Engineering a natural ligand-based CAR: directed evolution of the stress-receptor Nkp30. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 165-176.	4.2	10
48	Ly49G2 receptor blockade reduces tumor burden in a leukemia model but not in a solid tumor model. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 655-662.	4.2	6
49	Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1105-1112.	3.1	5
50	Challenges of creating effective chimeric antigen receptors for cancer therapy. <i>Immunotherapy</i> , 2013, 5, 783-785.	2.0	4
51	A Chimeric Antigen Receptor That Binds to a Conserved Site on MICA. <i>ImmunoHorizons</i> , 2020, 4, 597-607.	1.8	4
52	Innate and adaptive immunity in the human female reproductive tract: influence of the menstrual cycle and menopause on the mucosal immune system in the uterus. <i>Reproductive Medicine and Assisted Reproductive Techniques Series</i> , 2008, , 493-523.	0.1	3
53	Preclinical Studies in CAR T Cell Development. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S205-S207.	0.4	0
54	IMMU-17. TARGETING GLIOBLASTOMA WITH DNAM-1-BASED CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS. <i>Neuro-Oncology</i> , 2019, 21, vi122-vi122.	1.2	0

#	ARTICLE	IF	CITATIONS
55	Chimeric NKG2D receptor expressing T cells require host immune cells for anti-tumor efficacy. FASEB Journal, 2008, 22, 1076.10.	0.5	0